Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension - Takeaways - MDSpire

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension

  • By

  • Xiaopei Cui

  • Xiaoyu Hu

  • Xiaoteng Qin

  • Haijun Li

  • Xia Xu

  • Hui Liu

  • Qiushang Ji

  • May 21, 2026

Share

  • 1

    Selexipag-based triple therapy significantly improved exercise capacity and right heart function in Chinese patients with pulmonary arterial hypertension.

  • 2

    In a study of 153 patients, 65.8% achieved WHO FC II after 29 weeks of selexipag treatment, indicating improved functional status.

  • 3

    The 6-minute walk distance increased significantly from 414 m to 480 m, and NT-proBNP levels decreased, reflecting better clinical outcomes.

  • 4

    Risk stratification improved, with the proportion of patients meeting three low-risk criteria rising from 12.3% to 50.7% during follow-up.

  • 5

    The study suggests that initial triple therapy with selexipag may enhance long-term prognosis for patients with pulmonary arterial hypertension.

Original Source(s)

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension

  • by Xiaopei Cui, Xiaoyu Hu, Xiaoteng Qin, Haijun Li, Xia Xu, Hui Liu, Qiushang Ji

  • May 21, 2026

Related Content

LC9 Scores Tied to Better Lung Health in NHANES Analysis

Cross-sectional study linked higher cardiovascular health scores with fewer respiratory symptoms and higher lung function measures among US adults

Flu Hospitalization Tied to Diabetes Risk

A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.

Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults

In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United S...